German biotech drug jobs up 14% in 2007
The biotechnology group of Germany's research-based drugmakers' association (VFA) has published its annual report on the state of the sector, titled: Medical Biotechnology in Germany 2008. Speaking at the Berlin launch of the Boston Consulting Group study commissioned by the VFA bio, Frank Mathias, the chairman of the trade body and a board member of Martinsried-based MediGene AG, said: "4,000 new jobs, an increase of 14% in only one year, that is the proud balance sheet of medical biotechnology in Germany. The 'biotechnology job engine' is shifting into gear."
The VFA noted that the BSG annual report is the only study of its kind to document all activities within the range of the medical biotechnology in Germany - in start-ups as well as in large-scale enterprises. The biotechnology drug manufacturing sector achieved a combined sales, license income and milestone payments increase of 24% year-on-year.
46% rise in Phase III drug candidates
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze